

# VU Research Portal

## Het landschap van combinatie therapieën voor glioblastoom

Houweling, Megan

2023

**DOI (link to publisher)**  
[10.5463/thesis.406](https://doi.org/10.5463/thesis.406)

**document version**  
Publisher's PDF, also known as Version of record

[Link to publication in VU Research Portal](#)

**citation for published version (APA)**  
Houweling, M. (2023). *Het landschap van combinatie therapieën voor glioblastoom*. [, Vrije Universiteit Amsterdam]. <https://doi.org/10.5463/thesis.406>

### General rights

Copyright and moral rights for the publications made accessible in the public portal are retained by the authors and/or other copyright owners and it is a condition of accessing publications that users recognise and abide by the legal requirements associated with these rights.

- Users may download and print one copy of any publication from the public portal for the purpose of private study or research.
- You may not further distribute the material or use it for any profit-making activity or commercial gain
- You may freely distribute the URL identifying the publication in the public portal

### Take down policy

If you believe that this document breaches copyright please contact us providing details, and we will remove access to the work immediately and investigate your claim.

**E-mail address:**  
[vuresearchportal.ub@vu.nl](mailto:vuresearchportal.ub@vu.nl)

# Table of Contents

<b>Chapter 1</b>	General introduction and outline	<b>7</b>
<b>Chapter 2</b>	Screening of predicted synergistic multi-target therapies in glioblastoma identifies new treatment strategies	<b>29</b>
<b>Chapter 3</b>	A real-world toxicity-atlas shows that adverse events of combination-therapies commonly result in additive interactions	<b>63</b>
<b>Chapter 4</b>	Radio-sensitizing effect of MEK inhibition in glioblastoma <i>in vitro</i> and <i>in vivo</i>	<b>101</b>
<b>Chapter 5</b>	Data-driven prioritization and preclinical evaluation of therapeutic targets in glioblastoma	<b>119</b>
<b>Chapter 6</b>	Kinome rewiring after EGFR inhibition highlights potential new kinase targets for multi-target therapy against GBM	<b>145</b>
<b>Chapter 7</b>	Longitudinal drug synergy assessment using convolutional neural network image-decoding of glioblastoma single-spheroid cultures	<b>175</b>
<b>Chapter 8</b>	Summary and Discussion	<b>203</b>
<b>Chapter 9</b>	Nederlandse samenvatting	<b>213</b>
<b>Chapter 10</b>	Appendices	<b>221</b>